Indivior Pharmaceuticals (INDV) Other Non-Current Liabilities (2021 - 2026)

Indivior Pharmaceuticals' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $21.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 23.53% year-over-year to $21.0 million; the TTM figure through Mar 2026 stood at $21.0 million (up 23.53% YoY), while the FY2025 annual figure was $21.0 million, up 16.67% from the prior year.
• Other Non-Current Liabilities was $21.0 million for Q1 2026 at Indivior Pharmaceuticals, roughly flat from $21.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $428.0 million in Q4 2022 to a low of $17.0 million in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $73.0 million across 5 years, with a median of $21.0 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 463.16% in 2022, then plunged 92.76% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $428.0 million in 2022, then slumped by 92.76% to $31.0 million in 2023, then slumped by 41.94% to $18.0 million in 2024, then gained by 16.67% to $21.0 million in 2025, then changed by 0.0% to $21.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $21.0 million (Q1 2026), $21.0 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.